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Introduction: Breast cancer (BrC) is the most
common non-dermatologic cancer in women.
It frequently metastasizes to lung, liver and bone, while the uri-
nary bladder is considered as an unusual site for BrC metas-
tases. 
Materials and methods: Four years after her first oncologic sur-
gical approach, a known BrC patient complained of a left flank
pain, dysuria and urgency. Computed tomography (CT scan)
imaging showed an irregular thickening of the left bladder wall
and bilateral hydronephrosis. 
Results: A bladder metastases from BrC was diagnosed based on
a histological examination of a transurethral resection of the
bladder (TURB-T) specimen.
Conclusions: In patients with a history of BrC, urinary bladder
screening is not needful. However, if low urinary symptoms per-
sist, an evaluation of the bladder should be considered to rule
out metastatic involvement.
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of 2013 she presented with painless right breast mass.
A mammogram demonstrated a large high dense soft
mass lesion in the upper outer quadrant of the right
breast (maximum diameter 16 cm). A Tru-cut needle
biopsy showed 2 foci of invasive ductal carcinoma of 10
and 6 mm (immunohistochemistry was estrogen recep-
tor (ER) 95% - progesterone receptor (PgR) 40% - Ki67
40% - human epidermal growth factor receptor 2
(HER2) negative and ER 95% - PgR 10% - Ki67 15% -
HER2 negative, respectively). Tumour clinical stage was
T1cN1M0. Neoadjuvant chemotherapy was started
(FEC-75 q21 x4 + Paclitaxel 80 mg q7x12) and a right
mastectomy with ipsilateral axillary lymph node dissec-
tion was done in August 2014. Pathology revealed inva-
sive ductal carcinoma (IDC) with some elements of atypi-
cal ductal hyperplasia (ADH-DIN1b) and negative mar-
gins. All six removed lymph nodes were involved, one of
which presented perineural invasion. Tumour patholog-
ical stage was pT1c(m)/G2/N2a(6+/6)/M0 - luminal B
(stage IIIA). ER and PgR were positive (ER 95%, PgR
50%), Ki67 1% and HER2 were negative.
The patient underwent adjuvant radiotherapy from
November to December 2014 and hormonal adjuvant
treatment with Letrozole was administrated from
September 2014 to August 2016. She had been on regular
follow-up every 6 months until November 2016, when
the patient suffered from left subcutaneous inguinal mass.
Excisional biopsy showed a metastasis from the primary
BrC with negative margins. Immunohistochemistry
showed ER positive (100%), PgR negative, Ki67 40% and
HER2 negative. 
In January 2017, a follow-up total-body CT scan dis-
played left enlarged inguinal lymph nodes. Bone scintig-
raphy was negative. From February 2017, Letrozole was
substituted with Fulvestrant, which was continued until
April 2018. At the end of April 2018 a new CT scan
showed increasing of lymph node disease (left common
iliac lymph nodes, internal obturator lymph nodes and
left inguinal lymph nodes).
The patient took part in the phase II trial of the CDK4/6
inhibitor Palbociclib as single agent or in combination
with the same endocrine therapy (ET) received prior to
disease progression, in patients with hormone receptor
positive (HR+) HER2 negative metastatic breast cancer
(mBrC) (TREnd trial).
At the end of the first cycle she presented to our attention
with left flank pain, dysuria, urge incontinence and
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INTRODUCTION
Breast adenocarcinoma is the most frequently diagnosed
malignancy in women, with more than 1.6 million new
cancer cases diagnosed worldwide (25% of all cancers).
BrC remains the leading cause of death for cancer in
women, despite increased screening programs and
advanced therapies, and its mortality is mainly due to
metastatic disease. Common sites of BrC metastasis are
lung, liver, bone, lymph nodes and skin while other organs
are less frequently involved. Bladder metastasis from solid
tumours are rare, accounting for up 4.5% of all bladder
neoplasms (1). Most bladder metastasis are due to direct
infiltration from peripheral organs, such as colon and rec-
tum, prostate and cervix. Metastasis from distant organs
are extremely rare and reported sporadically. The most
common are related to stomach and lung tumours as well
as melanomas. BrC accounts for about 2.4% cases of all
bladder metastasis (1). In most instances, bladder metas-
tases from BrC are associated with other metastatic involve-
ment of pelvic organ with a very poor survival (2, 3). 
CASE REPORT
We present the clinical case of a 57 years-old woman
with a negative family history regarding BrC. At the end
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increasing creatinine. Abdominal CT scan displayed thick-
ening of the posterior-left bladder wall with bilateral grade
I-II hydronephrosis. Cystoscopy showed inflammatory
changes and suspicious bladder wall thickening. 
Transurethral resection of bladder tumour (TURB-T) was per-
formed. Pathology revealed muscular invasive anaplastic
cells consistent with the known primary breast adenocar-
cinoma. Microscopically, the bladder layers showed a dif-
fuse infiltration by large size carcinomatous cells displaying
round nuclei, distinct nucleoli with a diffuse pattern, with-
out obvious ductal or glandular structure. The urinary
transitional epithelium was intact and ulcerated, without
dysplastic or neoplastic changes. (Figures 1, 2) The mus-
cular layer was deeply involved. Neoplastic cells were ER
and PgR positive, Cytocheratin 7 positive, GCDFP 15 pos-
itive and Mammoglobin positive. Ki67 immunostaining
was markedly increased. Nowadays, the patient is contin-
uing the therapy with Palbociclib and Fulvestrant. A 3-
months follow-up cystoscopy and urine cytology didn’t
show any bladder recurrence.
CONCLUSIONS
Bladder metastases from BrC are uncommon. However,
literature reveals an increase of such occurrence over the
last few years, probably due to better imaging tech-
niques. Most cases are diagnosed after the diagnosis of
primary BrC and are usually associated with other
metastatic sites. Although routine screening of the lower
urinary tract is not mandatory for all patients, women
presenting with urinary symptoms should be evaluated
in order to exclude a bladder metastasis. The imaging
should include ultrasound, CT and/or MRI scan. Once
imaging and/or cystoscopy show a bladder neoplasm in
a patient with a BrC history, a TURB-T is mandatory.
Chemotherapy and/or hormonal therapy, if not already
ongoing, should started as soon as a diagnosis is con-
firmed. Generally, the prognosis is poor unless bladder
metastases represents the only metastatic site (3).
Our reported case confirm that bladder metastases may
occur late after the diagnosis of the primary tumours.
Such data support the need for accurate urological fol-
low-up and early intervention if such clinical state is sus-
pected. 
DISCUSSION
Secondary tumours of the urinary bladder are rare and
the majority of them are due to the direct extension of
another pelvic neoplasm (4). The minority are metastases
originating from lymphoma or from solid tumour such
as lung, breast cancers and melanoma. 
Possible mechanisms are through vascular and lymphat-
ic dissemination or direct retroperitoneal invasion (5). 
To date, approximately 55 cases of urinary bladder
metastasis from BrC have been reported in literature (3).
In the majority of reported cases, the urinary bladder
lesions from BrC were part of a systemic dissemination
and multiple organ involvement. This indicates that
bladder metastases are usually late complications of pri-
mary disease (6). However, a solitary metastasis to the
urinary bladder had also been reported (7, 8). Metastases
start from the outer layer of bladder wall and advance
towards the bladder lumen (9). Urinary symptoms cor-
relate with the advancement of this growth. Early stages
of BrC bladder metastases might be asymptomatic, while
the most common presenting symptoms are low urinary
tract symptoms (LUTS), flank or abdominal pain,
hydronephrosis, and haematuria (9).
Our patient did not present with macroscopic haema-
turia. Instead, she complained from recurrent dysuria,
urge incontinence and progressive renal failure. Flank
pain was later the major weakening symptom that
allowed the investigation through CT scan imaging. 
Diagnostic workshop needs imaging (ultrasound and CT
scan), direct visualisation of the bladder mucosa by cys-
toscopy, and histological confirmation of a specimen
obtained by biopsy or TURB-T. Cystoscopy findings vary
and comprehend solid tumour, inflammatory patches,
and thickened bladder wall with intact overlying
mucosa. In our patient cystoscopy revealed suspicious
bladder wall thickening and non-specific inflammatory
areas. Feldman et al. affirm that assessment should also
include further imaging evaluation, citing a case with
negative cystoscopy despite strong evidence of bladder
wall involvement from the patient’s symptoms, ultra-
sound and CT scan (10). Magnetic resonance imaging
The submucosal layer of the urinary bladder is expanded 
by medium and large size atypical cells, poorly
differentiated, that diffusely infiltrate the muscularis propria. 
The transitional epithelium is intact, without any dysplastic
and neoplastic changes or relation/connection to the
neoplastic elements. Hematoxylin-eosin stain (20x).
Figure 1. 
Immunohistochemistry staining is diffusely positive for
estrogen receptor in neoplastic cells, otherwise the
transitional epithelium of urinary bladder is completely
negative (20x).
Figure 2. 
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(MRI) scan would help in definitive confirmation of neo-
plastic bladder infiltration and it would help in precise
local cancer staging. PET-CT scan may reveal other
metastases. Patient assessment should incorporate check
of blood serum CA 15-3 level which remains the most
sensitive tumour marker in BrC follow-up (11).
The metastatic pattern of BrC may be related to the histo-
logic type of cancer (10). It has been suggested that infil-
trating lobular carcinoma (ILC) has a higher bladder
metastatic rate in comparison with infiltrating ductal carci-
noma (IDC) representing approximately 90% of BrC (3). 
Some reports have related the likelihood of developing
bladder metastases with the presence of positive lymph
nodes at first diagnosis of BrC or with steroid treatment
(11). Patients who have been administrated prolonged
steroid therapy may develop unusual metastases due to
the possible influence of immune-suppressive effects on
carcinoma spreading routes. 
Immunohistochemistry is an indispensable adjunct in the
correct diagnosis of metastatic tumours in all sites.
Common markers for suspected breast tumours include
the expression of cytokeratin, CK-7, CK-18, CK-19, CK-
20, GCDFP-15 and ER/PgR (8). In the present case, posi-
tive CK-7 and CD-138, and negative CD-20 helped the
pathologist in confirming the diagnosis of metastatic BrC. 
Some authors reported differences in hormonal (ER and
PgR) and HER2 expression between primary and
metastatic tissue, with discordance rates ranging from 24
to 39% (6, 12). 
Bladder metastases from BrC usually occurs a few
months after the initial diagnosis of the primary tumour,
but they might also occur years later (3, 10). However, it
is possible of bladder metastases being present at the
time of first diagnosis of BrC, like in the case reported by
Shah et al. (8), whereby acute renal failure due to the
ureteral obstruction was the presenting sign. In our
patient the bladder metastasis was identified 4 years after
the initial diagnosis of BcR.
The standard treatment of urinary bladder metastases
from BrC involves chemotherapy and hormonal therapy.
Radiotherapy might be used only to control bladder
bleeding. In case of obstructive uropathy, percutaneous
drainage or ureteric catheterization should be performed
to optimise renal function before starting chemotherapy. 
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